Evidence map›Paper›PMID 40528055›Full record

ArticleCell biochemistry and biophysics2025

Evaluation of Therapeutic Potential of a Selective 5α-reductase Inhibitor against Glioblastoma: Molecular Docking and In Vitro Insights.

Anil Sharma, Satvika Sharma, Jasmine Sati, Vishwash Bhardwaj, Tanzeer Kaur, Devinder Kumar Dhawan, Neelima Dhingra, Vijayta D Chadha

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anil SharmaCentre for Nuclear Medicine, Panjab University, Chandigarh, India.
Satvika SharmaDepartment of Biophysics, Panjab University, Chandigarh, India.
Jasmine SatiCentre for Nuclear Medicine, Panjab University, Chandigarh, India.
Vishwash BhardwajDepartment of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.
Tanzeer KaurDepartment of Biophysics, Panjab University, Chandigarh, India.
Devinder Kumar DhawanDepartment of Biophysics, Panjab University, Chandigarh, India.
Neelima DhingraDepartment of Pharmaceutical Chemistry, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India. neelimad08@pu.ac.in.
Vijayta D ChadhaCentre for Nuclear Medicine, Panjab University, Chandigarh, India. vdchadha@pu.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various experimental and clinical reports highlight the increased expression of androgen receptors (AR) in Glioblastoma (GBM) biopsies which indicates that targeting the ARs might be a rational treatment solution for glioma. In the same light, the present study aimed to synthesise a steroidal androsten analogue and evaluate its specificity and therapeutic potential in C6 glioma cell lines. Taking into consideration the 5α reductase inhibitory activity of the reported esters and based on the observation of the importance of the electronegative group at C-6 of the steroidal skeleton, a steroidal androsten analogue viz: 5α, 6β-dibromo derivative of 17-Oxo-5-androstane-3β-yl ester was synthesised and assessed for its specificity in targeting AR in in-silico and in vitro conditions. Further, the synthesised compound was assessed for its therapeutic potential by performing cytotoxicity assay, wound healing migration assay and transwell Cell Invasion Assay. High D score in the in-silico study indicated specificity and higher binding affinity of the synthesised compound towards androgen receptor as compared to the reference drug finasteride. MTT assay performed in C6 rat glioma cell line showed significant cytotoxicity with IC

Indexed as

5-alpha Reductase InhibitorsAntineoplastic AgentsGlioblastomaMolecular Docking SimulationAnimalsCell Line, TumorCell MovementCholestenone 5 alpha-ReductaseHumansRatsReceptors, Androgen5-alpha Reductase InhibitorsAntineoplastic AgentsCholestenone 5 alpha-ReductaseReceptors, Androgen5α-reductaseAndrogen receptor specificityC6 cellsCytotoxicitySteroidal derivatives

Identifiers

PMID40528055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.